During the current project period, Developmental Funds have been essential to maintaining and extending the research vitality of the scientific Programs in the Sidney Kimmel Comprehensive Cancer Center (SKCCC).
Specific aims of the SKCCC Developmental Funds are to: 1) Recruit cancer researchers in the areas of strategic need. 2) Support staff investigators who are critical to the activities of the SKCCC. 3) Provide funding for the development of new CCSG shared resources. Use of these funds is tightly linked to the formal planning and evaluation activities of the SKCCC. The funds have been used to recruit new investigators and to provide support for developing Shared Resources. These funds have been used primarily to build scientific strength in a number of Research Programs. During the current project period, 16 new investigators were recruited using Developmental Funds, 51 new externally funded grants were awarded to new investigators ($6.9 million annual direct costs) and another 15 are pending. A total of 325 peer-reviewed articles were published by new investigators. Developmental Funds for Shared Resources were also used to support a Rapid Autopsy Core, which is a fully established Shared Resource in this renewal application. In addition, Developmental Funds are requested to continue new investigator recruitment, develop new Shared Resources and provide support to staff investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-57
Application #
9944482
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
57
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Hyman, David M; Rizvi, Naiyer; Natale, Ronald et al. (2018) Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res 24:2749-2757
Guo, Hong; Barberi, Theresa; Suresh, Rahul et al. (2018) Progression from the Common Lymphoid Progenitor to B/Myeloid PreproB and ProB Precursors during B Lymphopoiesis Requires C/EBP?. J Immunol 201:1692-1704
Tosoian, Jeffrey J; Guedes, Liana B; Morais, Carlos L et al. (2018) PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer Prostatic Dis :
Tran, Phuong T; Meeker, Alan K; Platz, Elizabeth A (2018) Association between statin drug use and peripheral blood leukocyte telomere length in the National Health and Nutrition Examination Survey 1999-2002: a cross-sectional study. Ann Epidemiol 28:529-534
Pallavajjala, Aparna; Kim, Daehwan; Li, Tongbin et al. (2018) Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia. Leuk Lymphoma 59:1231-1238
Dean, Lorraine T; Moss, Shadiya L; Ransome, Yusuf et al. (2018) ""It still affects our economic situation"": long-term economic burden of breast cancer and lymphedema. Support Care Cancer :
Song, Mingyang; Vogelstein, Bert; Giovannucci, Edward L et al. (2018) Cancer prevention: Molecular and epidemiologic consensus. Science 361:1317-1318
Weber, Kari A; Heaphy, Christopher M; Joshu, Corinne E et al. (2018) Racial differences in maternal and umbilical cord blood leukocyte telomere length and their correlations. Cancer Causes Control 29:759-767
Haffner, Michael C; Taheri, Diana; Luidy-Imada, Eddie et al. (2018) Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proc Natl Acad Sci U S A 115:E8580-E8582
Nauman, Gina; Gray, Javaughn Corey; Parkinson, Rose et al. (2018) Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants (Basel) 7:

Showing the most recent 10 out of 2393 publications